Ever Supreme (6712) is registered for pre-OTC, recommend price is NT$50 per share. Benefited from the RGSCTT in early September, autologous cell therapy will bring growth of revenue in the first quarter next year, and is expected to achieve more than 200 millions annually, and achieve breakeven.
In addition, cell manufacturing site of Ever Supreme located in the Central Taichung Science Park has been established with PIC/S GMP specifications, and the inspection was completed; it will be used as a base for cell preparation in the future. Plus the combination of front-end R&D and back-end clinical trials done in medical institutions, the company is expected to establish a standard and a leading position in new cell drugs manufacturing.
.jpg)
.jpg)